Cue Biopharma Analyst Ratings
BenzingaApr 9 08:20 ET
Oppenheimer Maintains Outperform on Cue Biopharma, Maintains $10 Price Target
BenzingaApr 9 08:22 ET
Oppenheimer Remains a Buy on Cue Biopharma (CUE)
TipRanksApr 9 07:35 ET
Cue Biopharma (CUE) Gets a Buy From Stifel Nicolaus
TipRanksApr 9 07:07 ET
Cue Biopharma Analyst Ratings
BenzingaApr 3 12:00 ET
Piper Sandler Remains a Buy on Cue Biopharma (CUE)
TipRanksApr 3 07:06 ET
Cue Biopharma Analyst Ratings
BenzingaMar 13 09:00 ET
Analysts Offer Insights on Healthcare Companies: Cardinal Health (CAH), Intellia Therapeutics (NTLA) and Cue Biopharma (CUE)
TipRanksFeb 26 08:10 ET
Cue Biopharma (CUE) Gets a Buy From Piper Sandler
TipRanksFeb 20 07:45 ET
Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (BEAM), KalVista Pharmaceuticals (KALV) and Cue Biopharma (CUE)
TipRanksNov 13, 2023 14:10 ET
Analysts Conflicted on These Healthcare Names: Cue Biopharma (CUE) and Mirati Therapeutics (MRTX)
TipRanksNov 7, 2023 00:41 ET
Piper Sandler Maintains Overweight on Cue Biopharma, Raises Price Target to $8
BenzingaNov 6, 2023 10:40 ET
Cue Biopharma Analyst Ratings
BenzingaNov 6, 2023 10:40 ET
Analysts Offer Insights on Healthcare Companies: Cue Biopharma (CUE), Zoetis (ZTS) and CymaBay Therapeutics (CBAY)
TipRanksNov 6, 2023 07:51 ET
Cue Biopharma (CUE) Gets a Buy From Piper Sandler
TipRanksAug 10, 2023 09:16 ET
JMP Securities Keeps Their Buy Rating on Cue Biopharma (CUE)
TipRanksAug 10, 2023 00:15 ET
Oppenheimer Assumes Cue Biopharma at Outperform, Announces Price Target of $10
BenzingaJun 26, 2023 06:50 ET
Analysts Conflicted on These Healthcare Names: Cue Biopharma (CUE) and Corvus Pharmaceuticals (CRVS)
TipRanksJun 15, 2023 09:30 ET
Stifel Reiterates Buy on Cue Biopharma, Maintains $8 Price Target
BenzingaJun 15, 2023 08:42 ET
Cue Biopharma (CUE) Receives a Buy From Piper Sandler
TipRanksJun 15, 2023 07:55 ET
No Data
No Data